Trial Profile
A Phase 1B Study to Evaluate the Safety and Induction of Immune Response of CRS-207 in Combination With Pemetrexed and Cisplatin as Front-line Therapy in Adults With Malignant Pleural Mesothelioma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs CRS 207 (Primary) ; Cisplatin; Cyclophosphamide; Pemetrexed
- Indications Malignant-mesothelioma
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Aduro BioTech
- 01 Jul 2019 Results published in the Clinical Cancer Research
- 08 Jan 2019 Planned End Date changed from 1 Dec 2018 to 1 Jun 2019.
- 08 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2019.